Cargando…
ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program
Basal subtype cancers are deadly malignancies but the molecular events driving tumor lethality are not completely understood. Ataxia-Telangiectasia Group D Complementing gene (ATDC, also known as TRIM29), is highly expressed and drives tumor formation and invasion in human bladder cancers but the fa...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499660/ https://www.ncbi.nlm.nih.gov/pubmed/30643195 http://dx.doi.org/10.1038/s41388-018-0646-9 |
_version_ | 1783415812580704256 |
---|---|
author | Palmbos, Phillip L. Wang, Yin Bankhead, Armand Kelleher, Alan J. Wang, Lidong Yang, Huibin Ahmet, McKenzie L. Gumkowski, Erica R. Welling, Samuel D. Magnuson, Brian Leflein, Jacob Hiles, Guadalupe Lorenzatti Abel, Ethan Dziubinski, Michele L. Urs, Sumithra Day, Mark Ljungman, Mats E. Simeone, Diane M. |
author_facet | Palmbos, Phillip L. Wang, Yin Bankhead, Armand Kelleher, Alan J. Wang, Lidong Yang, Huibin Ahmet, McKenzie L. Gumkowski, Erica R. Welling, Samuel D. Magnuson, Brian Leflein, Jacob Hiles, Guadalupe Lorenzatti Abel, Ethan Dziubinski, Michele L. Urs, Sumithra Day, Mark Ljungman, Mats E. Simeone, Diane M. |
author_sort | Palmbos, Phillip L. |
collection | PubMed |
description | Basal subtype cancers are deadly malignancies but the molecular events driving tumor lethality are not completely understood. Ataxia-Telangiectasia Group D Complementing gene (ATDC, also known as TRIM29), is highly expressed and drives tumor formation and invasion in human bladder cancers but the factor(s) regulating its expression in bladder cancer are unknown. Molecular subtyping of bladder cancer has identified an aggressive basal subtype which shares molecular features of basal/squamous tumors arising in other organs and is defined by activation of a TP63-driven gene program. Here we demonstrate that ATDC is linked with expression of TP63 and highly expressed in basal bladder cancers. We find that TP63 binds to transcriptional regulatory regions of ATDC and KRT14 directly, increasing their expression, and that ATDC and KRT14 execute a TP63-driven invasive program. In vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis. These results link TP63 and the basal gene expression program to ATDC and to aggressive tumor behavior. Defining ATDC as a molecular determinant of aggressive, basal cancers may lead to improved biomarkers and therapeutic approaches. |
format | Online Article Text |
id | pubmed-6499660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-64996602019-07-14 ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program Palmbos, Phillip L. Wang, Yin Bankhead, Armand Kelleher, Alan J. Wang, Lidong Yang, Huibin Ahmet, McKenzie L. Gumkowski, Erica R. Welling, Samuel D. Magnuson, Brian Leflein, Jacob Hiles, Guadalupe Lorenzatti Abel, Ethan Dziubinski, Michele L. Urs, Sumithra Day, Mark Ljungman, Mats E. Simeone, Diane M. Oncogene Article Basal subtype cancers are deadly malignancies but the molecular events driving tumor lethality are not completely understood. Ataxia-Telangiectasia Group D Complementing gene (ATDC, also known as TRIM29), is highly expressed and drives tumor formation and invasion in human bladder cancers but the factor(s) regulating its expression in bladder cancer are unknown. Molecular subtyping of bladder cancer has identified an aggressive basal subtype which shares molecular features of basal/squamous tumors arising in other organs and is defined by activation of a TP63-driven gene program. Here we demonstrate that ATDC is linked with expression of TP63 and highly expressed in basal bladder cancers. We find that TP63 binds to transcriptional regulatory regions of ATDC and KRT14 directly, increasing their expression, and that ATDC and KRT14 execute a TP63-driven invasive program. In vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis. These results link TP63 and the basal gene expression program to ATDC and to aggressive tumor behavior. Defining ATDC as a molecular determinant of aggressive, basal cancers may lead to improved biomarkers and therapeutic approaches. 2019-01-14 2019-05 /pmc/articles/PMC6499660/ /pubmed/30643195 http://dx.doi.org/10.1038/s41388-018-0646-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Palmbos, Phillip L. Wang, Yin Bankhead, Armand Kelleher, Alan J. Wang, Lidong Yang, Huibin Ahmet, McKenzie L. Gumkowski, Erica R. Welling, Samuel D. Magnuson, Brian Leflein, Jacob Hiles, Guadalupe Lorenzatti Abel, Ethan Dziubinski, Michele L. Urs, Sumithra Day, Mark Ljungman, Mats E. Simeone, Diane M. ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program |
title | ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program |
title_full | ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program |
title_fullStr | ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program |
title_full_unstemmed | ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program |
title_short | ATDC Mediates a TP63-Regulated Basal Cancer Invasive Program |
title_sort | atdc mediates a tp63-regulated basal cancer invasive program |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499660/ https://www.ncbi.nlm.nih.gov/pubmed/30643195 http://dx.doi.org/10.1038/s41388-018-0646-9 |
work_keys_str_mv | AT palmbosphillipl atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT wangyin atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT bankheadarmand atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT kelleheralanj atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT wanglidong atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT yanghuibin atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT ahmetmckenziel atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT gumkowskiericar atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT wellingsamueld atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT magnusonbrian atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT lefleinjacob atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT hilesguadalupelorenzatti atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT abelethan atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT dziubinskimichelel atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT urssumithra atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT daymark atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT ljungmanmatse atdcmediatesatp63regulatedbasalcancerinvasiveprogram AT simeonedianem atdcmediatesatp63regulatedbasalcancerinvasiveprogram |